Abstracts tagged "matrix metalloproteinase (MMP) and osteoarthritis"

Abstract Number: 1945 • 2017 ACR/ARHP Annual Meeting
Repositioning Suramin As a Cartilage-Protective Drug
Laura-An Guns¹, Silvia Monteagudo¹, Maryna Kvasnytsia¹, Greet Kerckhofs¹, Jennifer Vandooren², Ghislain Opdenakker², Frederic Cailotto^1,3 and Rik Lories⁴, ¹Skeletal Biology and Engineering Research Center, KU Leuven, Leuven, Belgium, ²Rega Institute, KU Leuven, Leuven, Belgium, ³University of Lorraine, Nancy, France, ⁴Rheumatology, UZ Leuven, Leuven, Belgium
Background/Purpose: Drug repositioning is a recent pharmaceutical strategy to discover new uses for market-approved drugs with known safety profiles that can provide quick transition from…
Abstract Number: 2994 • 2016 ACR/ARHP Annual Meeting
Binding of Periostin to Discoidin Domain Receptor-1 (DDR1) Promotes Cartilage Degeneration By Inducing MMP-13 Expression
Yang Qing¹, Paolo Mignatti², Austin Ramme³, Thorsten Kirsch³, Jyoti Patel⁴ and Mukundan Attur⁴, ¹Medicine, New York University School of Medicine, New York, NY, ²Medicine, New York University, New York, NY, ³Orthopaedic Surgery, New York University, New York, NY, ⁴Rheumatology Research, NYU - Hospital for Joint Diseases, New York, NY
Background/Purpose: We and others have previously shown that periostin (Postn) expression is dramatically elevated in cartilage and sub-chondral bone in OA patients and surgical models…
Abstract Number: 1138 • 2015 ACR/ARHP Annual Meeting
Suppressor of Cytokine Signaling 1 Inhibits Interleukin-1β Induced Matrix Metalloproteinases Expression in Human Chondrocytes By Modulating p38-CREB- C/Ebpβ Pathway
You Jung Ha¹, Yong Seok Choi², Eun Ha Kang³, Kichul Shin⁴, Jaehyung Hur¹, Yeong Wook Song⁵ and Yun Jong Lee², ¹Division of Rheumatology, Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam-si, South Korea, ²Internal Medicine, Seoul National University Bundang Hospital, Seongnam-si, South Korea, ³Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam-si, South Korea, ⁴Rheumatology, SMG-SNU Boramae Medical Center, Seoul, South Korea, ⁵Department of Molecular Medicine and Biopharmaceutical Sciences, Graduate School of Convergence Science and Technology and College of Medicine Seoul National University, Seoul, South Korea
Background/Purpose: CAAT/enhancer-binding protein-beta (C/EBPb) is known to be a transcription factor regulating IL-1b-induced catabolic pathways, including the expression of matrix metalloproteinases (MMPs), in chondrocytes. Suppressor…
Abstract Number: 1011 • 2014 ACR/ARHP Annual Meeting
Fibroblast Growth Factor-2 and Its Receptor Antagonists in Osteoarthritis
Elina Nummenmaa¹, Mari Hamalainen¹, Teemu Moilanen^1,2, Katriina Vuolteenaho¹ and Eeva Moilanen¹, ¹The Immunopharmacology Research Group, University of Tampere School of Medicine and Tampere University Hospital, Tampere, Finland, ²Coxa Hospital for Joint Replacement, Tampere, Finland
Background/Purpose: The fibroblast growth factor (FGF) family represents an interesting group of molecules which are involved in the regulation of connective tissue development and metabolism.…
Abstract Number: 67 • 2013 ACR/ARHP Annual Meeting
Heparin-Binding Epidermal Growth Factor-Like Growth Factor (HB-EGF) As a Potential Mediator In Osteoarthritis
Richard F. Loeser¹ and David A. Long², ¹Section Of Molecular Medicine, Wake Forest School of Medicine, Winston-Salem, NC, ²Section Of Molecular Medicine, Wake Forest University, Winston-Salem, NC
Background/Purpose: We recently reported changes in gene expression in knee joint tissue from 12 week-old and 12 month-old mice after OA was induced by surgical…
Abstract Number: 47 • 2013 ACR/ARHP Annual Meeting
Exogenous Hydrogen Sulfide Donors Show Anti-Catabolic and Anti-Inflammatory Properties But Limited Anti-Oxidant Capability On Human Articular Osteoarthritic Chondrocytes
Elena F. Burguera^1,2, Angela Vela-Anero^2,3, Rosa Meijide-Failde² and Francisco J. Blanco^1,4, ¹Rheumatology Service, INIBIC-Hospital Universitario A Coruña, A Coruña, Spain, ²Servicio de Reumatología. Instituto de Investigación Biomédica de A Coruña (INIBIC). Complexo Hospitalario Universitario de A Coruña (CHUAC). Sergas. Universidade da Coruña (UDC)., Grupo de Bioingeniería Tisular y Terapia Celular (CBTTC-CHUAC). CIBER-BBN/ISCIII., A Coruña, Spain, ³Department of Medicine, University of A Coruña, A Coruña, Spain, ⁴Tissue Engineering and Cellular Therapy Group (CBTTC-CHUAC), CIBER BBN/ISCIII, A Coruña, Spain
Background/Purpose: Osteoarthritis (OA) is characterized by an imbalance between catabolism and anabolism, higher than normal levels of matrix metalloproteinases (MMPs), an increase in inflammatory markers…
Abstract Number: 204 • 2012 ACR/ARHP Annual Meeting
Characterization of Joint Disease in Mucopolysaccharidosis Type I Mice and the Effects of Enzyme Replacement Therapy
Patricia Oliveira¹, Guilherme Baldo², Fabiana Mayer², Barbara Martinelli², Luise Meurer³, Roberto Giugliani², Ursula Matte² and Ricardo M. Xavier⁴, ¹Rheumatology, Hospital de Clinicas de Porto Alegre, Porto Alegre, Brazil, ²Genetics, Hospital de Clinicas de Porto Alegre, ³Pathology, Hospital de Clinicas de Porto Alegre, ⁴Rheumatology Division, Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil
Background/Purpose: Mucopolysaccharidosis type I (MPS I) is a lysosomal disorder caused by deficiency of alpha-L-iduronidase, which leads to storage of glycosaminoglycans. Patients with MPS I…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].